Patterns & Phenotypes
Two promoters with distinct activities in different tissues drive the expression of heparanase in Xenopus
Article first published online: 9 NOV 2011
Copyright © 2011 Wiley Periodicals, Inc.
Volume 240, Issue 12, pages 2657–2672, December 2011
How to Cite
Bertolesi, G. E., Su, H. Y., Michaiel, G., Dueck, S. M., Hehr, C. L. and McFarlane, S. (2011), Two promoters with distinct activities in different tissues drive the expression of heparanase in Xenopus. Dev. Dyn., 240: 2657–2672. doi: 10.1002/dvdy.22770
- Issue published online: 9 NOV 2011
- Article first published online: 9 NOV 2011
- Manuscript Accepted: 3 OCT 2011
- Natural Sciences and Engineering Research Council of Canada
- Alberta Heritage Foundation for Medical Research (AHFMR)
- Canadian Institutes of Health Research Training Grant in Genetics, Child Health and Development
- Tier II Canada Research Chair in Developmental Neurobiology and an AHFMR Scientist
In Xenopus laevis embryos, heparanase, the enzyme that degrades heparan sulfate, is synthesized as a preproheparanase (XHpaL) and processed to become enzymatically active (XHpa active). A short nonenzymatic heparanase splice variant (XHpaS) is also expressed. Using immunohistochemistry, Western blot, and heparanase promoter analysis, we studied the dynamic developmental expression of the three heparanases. Our results indicate that (1) all three isoforms are maternally expressed; (2) XHpaS is a developmental variant; (3) in the early embryo, heparanase is localized to both the plasma membrane and the nucleus; (4) several tissues express heparanase, but expression in the developing nervous system is most evident; (5) two promoters with distinct activities in different tissues drive heparanase expression; (6) Oct binding transcription factors may modulate heparanase promoter activity in the early embryo. These data argue that heparanase is expressed widely during development, but localization and levels are finely regulated. Developmental Dynamics 240:2657–2672, 2011. © 2011 Wiley Periodicals, Inc.